ANDA 206676, held by Regcon Holdings. Cyproheptadine Hydrochloride.
As of Nov 16, 2026, ANDA 206676 (Cyproheptadine Hydrochloride), held by Regcon Holdings, was first approved by FDA on Apr 12, 2019, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitisAllergic conjunctivitis due to inhalant allergens and foodsMild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasmaCold urticariaDermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 12, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cyproheptadine Hydrochloride4MG · tablet;oral | Cyproheptadine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters